Journal of
Infectious Diseases and Immunity

  • Abbreviation: J. Infect. Dis. Immun.
  • Language: English
  • ISSN: 2141-2375
  • DOI: 10.5897/JIDI
  • Start Year: 2009
  • Published Articles: 87

Full Length Research Paper

Micafungin and caspofungin pharmacodynamics in patients with candidemia

Rawan Kassar
  • Rawan Kassar
  • Division of Infectious Diseases, University of Toronto, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
  • Google Scholar
Janis Chang
  • Janis Chang
  • Division of Infectious Diseases, University of Toronto, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
  • Google Scholar
Jerome Schentag
  • Jerome Schentag
  • School of Pharmacy, State University of New York, United States.
  • Google Scholar
Coleman Rotstein
  • Coleman Rotstein
  • Division of Infectious Diseases, University of Toronto, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada.
  • Google Scholar


  •  Received: 18 October 2018
  •  Accepted: 14 December 2018
  •  Published: 31 December 2018

References

Amsden GW, Ballow CH, Schentag JJ (1993). Population pharmacokinetic methods to optimizse antibiotic effects. Drug Investigation 5(5):256-268.
Crossref

 

Andes D, Ambrose PG, Hammel JP, Van Wart SA, Varsha I, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM (2011). Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrobial Agents and Chemotherapy 55(5):2113-2121.
Crossref

 

Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. (2010). In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida spp. Antimicrobial Agents and Chemotherapy 54(6):24979-2506.
Crossref

 

Barchiesi F, Spreghini E, Tomassetti S, Vittoria AD, Arzeni D, Manso E, Scalise G (2006). Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrobial Agents and Chemotherapy 50(8):2719-2727.
Crossref

 

Bow EJ, Evans G, Fuller J, Laverdiere M, Rotstein C, Rennie R, Shafran SD, Sheppard D, Carle S, Phillips P, Vinh DC (2010). Canadian clinical practice guidelines for invasive candidiasis in adults.Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults. The Canadian JJournal of IInfectious Diseases & Medical Microbiology 21(4):E122-1E150.

 

Chamilos G, Lewis RE, Albert N, Kontoyiannis DP (2007). Paradoxical effect of echinocandins across Candida species in vitro: Evidence for echinocandin-specific and Candida species-related differences. Antimicrobial Agents and Chemotherapy 51(6):2257-2259.
Crossref

 

Chen SC, Slavin MA, Sorrell TC (2011). Echinocandin antifungal drugs in fungal infections: A comparison. Drugs 71(1):11-41. Chmother
Crossref

 

Clemons KV, Espiritu M, Parmar R, Stevens DA (2006). Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrobial Agents and Chemotherapy 50(4):1293-1297.
Crossref

 

Cockcroft DW, Gault MH (1976). Prediction of creatinine clearance from serum creatinine. Nephron116(1):31-41.

 

Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SRBS, St-Germain G, Szeszs MW, Turnidge J (2013) Interlaboratory variability of Caspofungin MICs for Candida spp. using CLSA and EUCAST methods: Should the clinical laboratory be testing for this agent? Antimicrobial Agents and Chemotherapy 57(12):5836-5842.
Crossref

 

Fridkin SK (2005). The changing face of fungal infections in health care settings. Clinical Infectious Diseases 41(10):1455-1460.
Crossref

 

Hanley MJ, Abernethy DR, Greenblatt DJ (2010). Effect of obesity on the pharmacokinetics of drugs in humans. Clinical Pharmacokinetics 49(2):71-87.
Crossref

 

Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH (2000). The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118(1):146-155.
Crossref

 

Kuhn DM, George T, Chandra J, Mukhergee PK, Ghannoum MA (2002). Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrobial Agents and Chemotherapy 46(6):1773-1780.
Crossref

 

Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Kumar A, Simon D, Peters C, Ahsan M, Chateau D (2009). Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 136(5):1237-1248.
Crossref

 

Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Duration of hypotension before initation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical Care Medicine 34(6):1589-1596.
Crossref

 

Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA, Micafungin Invasive Candidiasis Working group (2007). Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial.Micafungin versus liposomal amphotericin B for candidemia and invasive candidiasis: a phase III randomized double-blind trial. The Lancet 369(9572):1519-1527.
Crossref

 

Magill SS, O'Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, Wilson LE, Kainer MA, Lynfield R, Greissman S, Ray SM, Beldavs Z, Gross C, Bamberg W, Sievers M, Concannon C, Buhr N, Warnke L, Maloney M, Ocampo V, Brooks J, Oyewumi T, Sharmin S, Richards K, Rainbow J, Samper M, Hancock EB, Leaptrot D, Scalise E, Badrun F, Phelps R, Edwards JR (2018). Changes in prevalence of health care-associated infections in U.S. Hospitals., Changes in prevalence of health care-associated infections in U.S. hospitals. New England Journal of Medicine 379:(18):1732-1744.
Crossref

 

Marcos-Zambrano P, Escribano P, Sanchez-Carrillo C, Guinea J (2016). Frequency of the paradoxical effect measured using the EUCAST procedure with micafungin, anidulafungin, and caspofungin against Candida species isolates causing candidemia. Antimicrobial Agents and Chemotherapy 61(1):e01584-16

 

Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rjinders BJA, Sheretz RJ, Warren D (2009). Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 49(1):1-45.
Crossref

 

Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect (2002). Comparison of caspofungin and amphotericin B for invasive candidiasis. New England Journal of Medicine 347(25):2020-2029.
Crossref

 

Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S, Harrison LH, Seaberg EC, Hajjeh RA, Teutsch SM 2005). Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infection Control and Hospital Epidemiology 26(6):540-547.
Crossref

 

National Committee for Clinical Laboratory Standards (2002). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, Wayne, Pa.

 

Nucci M, Anaissie, E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O (2010). Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clinical Infectious Diseases 51(3):295-303.
Crossref

 

Ostrosky-Zeichener L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Clearly J, Mangino JE, Lee J (2003). Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrobial Agents and Chemotherapy 47(10):3149-3154.
Crossref

 

Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN (2005). International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia International, open-label, non-comparative, clinical trial of . micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. European Journal of Clinical Microbiology & Infectious Diseases 24(10):654-661.
Crossref

 

Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH (2007). Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting.Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care unit setting. European Journal of Clinical Microbiology & Infectious Diseases 26:(4):271-276.
Crossref

 

Paderu P, Garcia-Effron G, Balashov S (2007). Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrobial Agents and Chemotherapy. 51(6):2253-2256.
Crossref

 

Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America (2009). Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48(5):503-535.
Crossref

 

Pappas PG, Rex JH, Lee J (2003). A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clinical Infectious Diseases 37(5):634-643.
Crossref

 

Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Diqumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN (2007). Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clinical Infectious Diseases 45(7):883-893.
Crossref

 

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ (2008). In vitro susceptibility of invasive isolates of Candida spp to anidulafungin, caspofungin, and micafungin: six years of global surveillance. Journal of Clinical Microbiology 46(1):150-156.
Crossref

 

Pfaller MA, Diekema DJ (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews 20(1):133-163.
Crossref

 

Reboli A, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ, Anidulafungin Study Group (2007). Anidulafungin versus fluconazole for the treatment of invasive candidiasis. New England Journal of Medicine 356(24):2472-2482.
Crossref

 

Wald A (1943). Tests of statistical hypotheses concerning several parameters when the number of observations is large. Transactions of the American Math Society 54:426-482.
Crossref

 

Walker LA, Gow NA, Munro CA (2010). Fungal echinocandin resistance. Fungal Genetics & Biology 47(2) :117–126.
Crossref

 

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 39(3):309-317.
Crossref

 

Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2006). Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. Clinical MicrobiolMicrobiology and Infection 12(2):170–177.
Crossref

 

Zilberberg MD, Shorr AF, Kollef MH (2008). Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infection Control Hospital Epidemiology 29(10):978-980.
Crossref